文献速递类风湿关节炎

类风湿因子与抗环瓜氨酸化肽抗体检测方法的性能特征可能影响类风湿关节炎的ACR/EULAR分类

Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2018-01-23

该研究分析了594例连续首次就诊风湿科患者(其中44例诊断为类风湿关节炎)及26例新诊断患者的样本,用6种类风湿因子(RF)检测法和7种抗环瓜氨酸化蛋白/肽抗体(ACPA)检测法评估技术性能与诊断性能,并分析性能差异对2010年ACR/EULAR分类的影响。结果显示不同检测法间数值一致性差,按厂商推荐的临界值时敏感度和特异度变异大,导致部分患者(RF为13%、ACPA为1%、RF/ACPA为9%)可能因所用检测法不同而被分类或不被分类为类风湿关节炎。

要点

  • 不同RF和ACPA检测法之间数值一致性差。
  • 按厂商临界值时,各检测法敏感度和特异度变异大,RF尤甚。
  • 使用不同检测法时,部分患者(RF为13%、ACPA为1%、RF/ACPA为9%)可能被分类或不被分类为类风湿关节炎。

核心结论

  • 由于RF和ACPA检测法及结果解读的协调性差,使用不同检测法时按2010年ACR/EULAR标准进行的类风湿关节炎分类可能不同。

研究设计与样本

  • 研究分析了594例连续首次就诊风湿科患者(其中44例诊断为类风湿关节炎)及26例新诊断类风湿关节炎患者的样本,用6种RF检测法和7种ACPA检测法进行评估。

主要发现

  • 不同检测法间分析性能存在差异,RF和ACPA检测法之间数值一致性差。
  • 所有检测法中,类风湿关节炎的似然比随抗体水平升高而增加。
  • RF检测法的受试者工作特征曲线下面积范围为0.676-0.709,ACPA检测法为0.672-0.769,仅部分ACPA检测法之间存在差异。
  • 按厂商推荐的临界值时,各检测法敏感度和特异度变异大,RF尤甚。
  • 根据所用检测法不同,部分患者(RF为13%、ACPA为1%、RF/ACPA为9%)可能被分类或不被分类为类风湿关节炎。

关键数值与推荐

  • RF检测法受试者工作特征曲线下面积范围为0.676-0.709。
  • ACPA检测法受试者工作特征曲线下面积范围为0.672-0.769。
  • 按厂商临界值时,可能因检测法不同而被分类或不被分类为类风湿关节炎的患者比例:RF为13%,ACPA为1%,RF/ACPA为9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rheumatoid factor (RF) and anti-cyclic citrullinated protein/peptide antibodies (ACPA) are integrated in the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for rheumatoid arthritis (RA). The objectives of this study were to evaluate the technical and diagnostic performance of different RF and ACPA assays and to evaluate whether differences in performance impact RA classification. METHODS: Samples from 594 consecutive patients who for the first time consulted a rheumatologist (44 of whom were diagnosed with RA) and 26 extra newly diagnosed patients with RA were analysed with six different RF assays (Menarini, Thermo Fisher, Inova, Roche, Abbott, Euroimmun) and seven different ACPA assays (Menarini, Thermo Fisher, Inova, Roche, Abbott, Euro Diagnostica, Euroimmun). RESULTS: We found differences in analytical performance between assays. There was poor numerical agreement between the different RF and ACPA assays. For all assays, the likelihood ratio for RA increased with increasing antibody levels. The areas under the curve of receiver operating characteristic analysis of the RF (range 0.676-0.709) and ACPA assays (range 0.672-0.769) only differed between some ACPA assays. Nevertheless, using the cut-off proposed by the manufacturer, there was a large variation in sensitivity and specificity between assays (mainly for RF). Consequently, depending on the assay used, a subgroup of patients (13% for RF, 1% for ACPA and 9% for RF/ACPA) might or might not be classified as RA according to the 2010 ACR/EULAR criteria. CONCLUSION: Due to poor harmonisation of RF and ACPA assays and of test result interpretation, RA classification according to 2010 ACR/EULAR criteria may vary when different assays are used.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Van Hoovels L, Jacobs J, Vander Cruyssen B, et al. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis. 2018. PMID: 29363510. doi:10.1136/annrheumdis-2017-212365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。